Coronavirus: Biontech / Pfizer vaccine patent dispute



[ad_1]

It is currently the sharpest weapon that Europe and the rest of the world have against Corona: BNT162b2, the corona vaccine from Biontech and Pfizer. It is in high demand and in short supply.

If no more vaccines are approved soon, Switzerland, for example, will not be able to immunize three-quarters of the population by the summer of 2021, as planned, simply because of the quantity ordered and deliveries. Projections are based on spring 2022 at the earliest.

[ad_2]